glp-1 and muscle growth Weighing the risk of treatment in older adults: Should we be concerned about sarcopenic obesity? Muscle loss and GLP-1R agonists

Gastrointestinal side-effects occurred more frequently in the liraglutide arm, the most frequent being vomiting ( n = 6, 46.2%) (Table 3)

The British Journal of Nutrition, 91 (2), 263-269

The broader population need is visible because PAHO reported that 67.5% of adults in Latin America had excess weight, which leaves a large future base for medication and companion nutrition adoption

Additionally, tirzepatide may cause fewer gastrointestinal side effects and provides extra benefits for patients with type 2 diabetes or increased cardiovascular risk, including improved glucose control and reduced cardiovascular event risk

24 Compounding is a commercial activity, not a regulatory compliance exercise in the context of creating an ANDA

There were many stories I heard, but there was one that repeated itself with such consistency that you couldnt ignore it